Navigation Links
U.S. Navy Receives Funding for Further Development of Hemopure(R)
Date:5/8/2008

CAMBRIDGE, Mass., May 8 /PRNewswire-FirstCall/ -- Biopure Corporation (Nasdaq: BPUR) announced today that the Naval Medical Research Center (NMRC) has received new funding of approximately $3.4 million for the development of Hemopure(R) (HBOC-201). These funds are being granted through the Department of Defense for a project entitled: A Multifunctional Blood Substitute for Field Resuscitation of Polytrauma Combat Casualties with Brain Injury and Concomitant Hemorrhagic Shock.

Biopure is collaborating with the NMRC to develop HBOC-201 as a platform for the first multifunction blood substitute for trauma patients. The preclinical work towards a multifunctional product for traumatic brain injury is expected to be conducted by the NMRC itself and other laboratories to be engaged by the NMRC. The project is part of the Post Traumatic Stress Disorder/Traumatic Brain Injury Research Program of the Office of the Congressionally Directed Medical Research Programs.

This funding for development toward an indication of traumatic brain injury is in addition to the $22.5 million previously allocated by Congress for the military for research of HBOC-201. Biopure anticipates that the work relating to the multifunction blood substitute development will begin as soon as certain agreements are completed. The company continues to support the NMRC's efforts toward lifting the clinical hold on the NMRC's investigational new drug application to conduct the pending, proposed clinical trial in trauma patients entitled "Restore Effective Survival in Shock (RESUS).

Biopure Corporation

Biopure Corporation develops, manufactures and markets pharmaceuticals, called oxygen therapeutics, that are intravenously administered to deliver oxygen to the body's tissues. Hemopure(R) [hemoglobin glutamer -- 250 (bovine)], or HBOC-201, is approved for sale in South Africa for the treatment of surgical patients who are acutely anemic. The company is developing Hemopure for other indications and is supporting the U.S. Navy's government-funded efforts to develop a potential out-of-hospital trauma indication. Biopure's veterinary product Oxyglobin(R) [hemoglobin glutamer -- 200 (bovine)], or HBOC-301, the only oxygen therapeutic approved for marketing by both the U.S. Food and Drug Administration and the European Commission, is indicated for the treatment of anemia in dogs. Biopure has sold approximately 200,000 units of Oxyglobin since its launch in 1998.

Statements in this press release that are not strictly historical are forward-looking statements, including any statements implying that any clinical trial will be initiated and/or carried out to completion, that preclinical study results will be as desired or that the FDA might lift the clinical hold on the RESUS trial. Actual results may differ materially from those projected in these forward-looking statements due to risks and uncertainties. These risks include, without limitation, uncertainties regarding the company's financial position, unexpected costs and expenses, possible delays related to clinical trials, determinations by the FDA, and unpredictable outcomes of preclinical and clinical trials. The company undertakes no obligation to release publicly the results of any revisions to these forward- looking statements to reflect events or circumstances arising after the date hereof. A full discussion of the company's operations and financial condition can be found in the company's filings with the U.S. Securities and Exchange Commission, including under the heading "Risk Factors" in the Form 10-Q filed on March 17, 2008, which can be accessed in the EDGAR database at the SEC Web site, http://www.sec.gov. The content of this press release does not necessarily reflect the position or the policy of the U.S. Government or the Department of Defense, and no official endorsement should be inferred.

Contact: Tiana Gorham

Biopure Corporation

(617) 234-6826

IR@biopure.com


'/>"/>
SOURCE Biopure Corporation
Copyright©2008 PR Newswire.
All rights reserved

Related medicine news :

1. UCSF receives funding for building from California stem cell agency
2. USC receives nearly $27 million in funding for new stem cell research facility
3. Amneal Pharmaceuticals Receives US FDA Approval for Three Generic Prescription Drugs; Two Using New FDA Electronic Filing Format
4. Presbyterian Hospital of Plano Receives Prestigious Texas Award for Performance Excellence
5. Boston Medical Center/Boston University School of Medicine researcher receives award
6. Canadian Company Receives Final Tender Approval From Rwanda For Vital AIDS Drug
7. Quatro Composites Receives ISO 9001:2000 and AS9100:2004 Certification
8. Vascular Insights Receives FDA Clearance for Infusion Catheter
9. Epitomics receives ISO 9001 certification for the production of Rabbit Monoclonal Antibodies.
10. NBCHs Community Coalitions Health Institute Receives CDC Grant
11. Weill Cornell receives funding to study creation of new elder abuse center
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/28/2017)... (PRWEB) , ... June 28, 2017 , ... ... ZEON) is pleased to announce that a two year study conducted by the ... Bromley Creek zeolite was successful in remediating potash brine-impacted groundwater. As a part ...
(Date:6/28/2017)... ... 28, 2017 , ... Designers Insurance Agency, a privately owned ... and DC, is announcing a cooperative charity event in conjunction with the Insight ... that lead to memory impairment. , The Insight Memory Care Center (IMCC) offers ...
(Date:6/27/2017)... ... June 27, 2017 , ... Nearly ... to survey data released today by the American Society for Dermatologic Surgery ... indicates the percentage of consumers considering a cosmetic medical procedure has doubled since ...
(Date:6/27/2017)... , ... June 27, 2017 , ... ... solution for many of the health care industry’s hospitals and provider groups, has ... financing portal for select customers. Parasail Health is a San Francisco health-finance startup ...
(Date:6/27/2017)... (PRWEB) , ... June 27, 2017 , ... From June ... The three-day event was held in Syracuse, New York, where EarQ is headquartered. , ... industry, how to connect with today’s savvy consumer, and the latest in hearing ...
Breaking Medicine News(10 mins):
(Date:6/7/2017)... -- Diplomat Specialty Infusion Group, a brand of Diplomat Pharmacy, Inc. (NYSE: ... Iowa location. The Iowa ... ISO 7 cleanroom—the standard needed to compound intravenous (IV) nutrition formulations. ... pollutants. "Our new cleanroom will ... our Iowa patients," said Phil Rielly ...
(Date:6/5/2017)... June 5, 2017 Kohll,s Pharmacy & Homecare is the ... the United States . The Raizer is a simple ... person up to an almost-standing position within a ... by one assistant and does not require any ... that a child can operate it, and lightweight ...
(Date:6/2/2017)... -- NxStage Medical, Inc. (Nasdaq:  NXTM), a leading medical technology company focused ... positive biochemical outcomes related to more frequent hemodialysis with ... be presented at the ERA-EDTA Congress being held June ... The research was conducted by the ... Europe (KIHDNEy) Cohort team with ...
Breaking Medicine Technology: